Gossamer Hopes To Stand Out In Crowded Spaces

The company plans to release topline results this year in ulcerative colitis and pulmonary arterial hypertension. In UC, especially, Gossamer is aiming for an opportunity that remains untapped.

Ulcerative colitis endoscopic biopsy — Gossamer gave updates on its ulcerative colitis and pulmonary arterial hypertension studies • Source: Shutterstock

Ulcerative colitis (UC) may be a highly crowded space, but Gossamer Bio, Inc. thinks its lead candidate, the Phase II GB004, could still address what it called an unmet need for a treatment in the space between anti-inflammatory drugs and biologics for patients with mild-to-moderate disease.

The company said during its fourth quarter and full year 2021 earnings call on 3 March that it expects to have topline results from the Phase II SHIFT-UC study of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

03 Jun 2025

• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.